Biologics News
ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., December 12, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
Biologics by McKesson is now the Exclusive Specialty Pharmacy Provider of XERMELO (telotristat ethyl), an FDA Approved Therapy for Carcinoid Syndrome Diarrhea
CARY, N.C., July 25, 2022 —Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has
VONJO (pacritinib), FDA Approved for Treatment of Intermediate or High-risk Myelofibrosis, Available at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by
PYRUKYND (mitapivat), FDA Approved for Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency, Available Exclusively at Biologics by McKesson
CARY, N.C., March 2, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
TARPEYO (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected
BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson
CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was